STK25

Serine/threonine-protein kinase 25 · O00506 · STK25 on Sugi Atlas →

19,615 patent compounds predicted against STK25, 16,665 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Pelitinib (SCHEMBL93756)	1.00	1/20
Pelitinib (SCHEMBL93757)	1.00	1/20
Ruxolitinib (SCHEMBL99225)	1.00	1/20
Ruxolitinib (SCHEMBL101279)	1.00	1/20
Bosutinib (SCHEMBL158390)	1.00	1/20
Ruxolitinib (SCHEMBL171319)	1.00	1/20
Dovitinib (SCHEMBL172687)	1.00	1/20
SCHEMBL256712	1.00	1/20
Fedratinib (SCHEMBL263741)	1.00	1/20
Dasatinib Anhydrous (SCHEMBL8226)	0.98	1/20
Dovitinib (SCHEMBL248083)	0.98	1/20
SCHEMBL99245	0.98	1/20
SCHEMBL99371	0.98	1/20
SCHEMBL103135	0.98	1/20
SCHEMBL98692	0.92	1/20
Dovitinib (SCHEMBL253137)	0.86	1/20
Dovitinib (SCHEMBL253994)	0.84	1/20
Ruxolitinib (SCHEMBL99771)	0.84	1/20
Ruxolitinib (SCHEMBL100078)	0.84	1/20
SCHEMBL101345	0.82	1/20

Clinical trials — most relevant to STK25 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors	PHASE1/PHASE2	NOT_YET_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers	PHASE1	RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors	PHASE1	UNKNOWN
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK25 binder may also engage these)

Protein	Name	Similarity
Q99KH8	—	1.000	Q99KH8 →
Q9Z2W1	—	1.000	Q9Z2W1 →
Q3SWY6	—	1.000	Q3SWY6 →
STK24	Serine/threonine-protein kinase 24	1.000	landscape →
B0LT89	—	0.997	B0LT89 →
Q99JT2	—	0.997	Q99JT2 →
STK26	Serine/threonine-protein kinase 26	0.995	landscape →
MAP2K7	Dual specificity mitogen-activated protein kinase kinase 7	0.991	landscape →
Q4KSH7	—	0.990	Q4KSH7 →
Q8AXB4	—	0.989	Q8AXB4 →
Q7YQL3	—	0.989	Q7YQL3 →
PAK3	Serine/threonine-protein kinase PAK 3	0.989	landscape →
Q9NB31	—	0.988	Q9NB31 →
PAK2	Serine/threonine-protein kinase PAK 2	0.987	landscape →
P08458	—	0.987	P08458 →
P35465	—	0.987	P35465 →
O61125	—	0.987	O61125 →
O35832	—	0.987	O35832 →
Q7YQL4	—	0.987	Q7YQL4 →
Q08E52	—	0.986	Q08E52 →
O88643	—	0.986	O88643 →
F4JTP5	—	0.986	F4JTP5 →
Q9Y884	—	0.986	Q9Y884 →
P13234	—	0.986	P13234 →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.985	landscape →
Q17850	—	0.985	Q17850 →
Q04899	—	0.985	Q04899 →
Q8BSK8	—	0.985	Q8BSK8 →
Q6TJY3	—	0.985	Q6TJY3 →
O35831	—	0.985	O35831 →